US stock futures rise as hopes emerge for a Mideast end to hostilities

💊 Apellis stock soars after Biogen deal, momentum score surges

Biogen Inc. is set to acquire Apellis Pharmaceuticals for $5.6 billion in cash, aiming to expand its rare-disease offerings and offset slowing multiple sclerosis revenue.

The deal, announced Tuesday, will provide Biogen with Apellis' approved drugs Empaveli and Syfovre, as well as access to late-stage kidney treatment felzartamab.

Apellis shareholders will receive $41 per share, a roughly 140% premium, plus up to $4 per share in milestone payments if Syfovre hits global annual sales of $1.5 billion to $2 billion between 2027 and 2030.

The Benzinga Edge Stock Rankings now provide a full analysis of APLS's price structure, showing that Apellis Pharmaceuticals' short-, medium- and long-term trends have all turned Positive. Benzinga reports.


✈️ Delta kicks off an earnings season focused on surging gas prices and the Iran war

When Delta Air Lines kicks off the first-quarter earnings season on Wednesday, the air carrier’s results and forecast will offer a deeper look at how well U.S. customers and companies can withstand surging oil and fuel prices due to the war in Iran.

Delta, along with Levi Strauss and Constellation Brands, will report this week after the U.S. economy in March, the first full month of the war, added more jobs than expected, although the war’s impact could be felt more acutely later on.

But even with no shortage of things for consumers to worry about, corporate America overall offered up more optimism than normal for the first quarter.

This week’s results, along with quarterly financials from the banks, tech companies and retailers in the weeks ahead, will put that rosier view to the test. MarketWatch reports.


💊 Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Neurocrine Biosciences is betting that a $2.9 billion acquisition of a biopharmaceutical company could speed up its strategy to start developing new treatments for obesity.

Soleno Therapeutics’ stock soared 34.5% in premarket trading on Monday after the deal was announced.

The Financial Times first reported that Neurocrine was inching closer to a deal to buy the company.

Neurocrine’s stock was down 2.8%. MarketWatch reports.


💊 Neurocrine to buy Soleno Therapeutics for $2.9 billion

Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker's expansion into metabolic disorders.

Neurocrine has offered $53 per Soleno share held, which represents a premium of about 34% to stock's last close.

Soleno shares, which had risen more than 30% in premarket trading after the Financial Times first reported the news, were halted. Reuters reports.


🚀 SpaceX's IPO could supercharge the entire space industry

SpaceX's IPO filing last week set the stage for what could be the largest IPO in history at a target valuation north of $2 trillion.

It could also provide a big boost beyond Elon Musk's own rocket company.

Shares of Rocket Lab surged roughly 10%; Planet Labs jumped more than 10%, and AST SpaceMobile climbed even more on the news.

The market's reaction provided something of a confirmation that a SpaceX public listing won't just benefit SpaceX shareholders.

It could change how the investment world views, and now re-rates, the entire space sector. Yahoo Finance reports.

Time (ET)/ Report/ Period

10:00 AM - ISM Services - March

“An investment in knowledge pays the best interest.”

– Benjamin Franklin

Sourced in: The Way to Wealth — GoodReads.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.